Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Erdosteine in Nonalcoholic Fatty Liver Disease
NCT07242222Phase 2Recruiting
- Sponsor
- Tanta University
- Start
- Nov 2025
- Primary completion
- Nov 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of erdosteine in non-alcoholic fatty liver disease (NAFLD), sponsored by Tanta University. Started Nov 2025; status: recruiting.
02
Drugs
erdosteine
03
Conditions
non-alcoholic fatty liver disease (NAFLD)
Beyond the preview
Go deeper on NCT07242222.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07242222.